Directorate Change

RNS Number : 1142F

Tekcapital plc

10 November 2015

 

Tekcapital plc

("Tekcapital" or the "Company")

Appointment of Non-Executive Director and Grant of Options

Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property services, announces that Robert Clell Miller, M.D., has been appointed to the Company's Board as a Non-Executive Director with immediate effect.

Dr. Miller is Vice Chairman of the Board of Trustees of Mayo Clinic Health System - Albert Lea and Austin.

Dr. Miller is also a Professor of Radiation Oncology at Mayo Clinic Jacksonville and is also Medical Director of Mayo Clinic's Operations in Northfield. Dr. Miller has over 20 years' experience in Radiation Oncology and is currently Editor in Chief of the Rare Tumours medical journal in Italy and the Advances in Radiation Oncology medical journal in the USA.

In addition to a medical degree from the University of Kentucky, Dr. Miller has undergraduate degrees in Business Administration and Engineering Physics from the University of Tulsa, a master's degree in Radiological Medical Physics from the University of Kentucky and an MBA from the University of Oxford, UK.

Clifford M. Gross, Executive Chairman of Tekcapital, said: "We are delighted to add Dr. Miller to the Board and believe his addition will provide significant business, medical and scientific expertise for future evaluations of medical technology and their opportunities for industrial scale commercialisation".

Additional information regarding Dr Robert Miller

Dr Robert Clell Miller, aged 52, is, or has been a director or partner of the following companies or partnerships during the past five years:

Current Directorships and Partnerships:	Directorships and Partnerships held in the previous 5 years:
Mayo Clinic Health System - Albert Lea and Austin	None

Grant of Options

Tekcapital also announces the grant of 120,000 options to subscribe for new ordinary shares of 0.4 pence each in the Company ("Ordinary Shares") (the "Options") to Dr Miller on 10 November 2015 (the "Grant Date"), in connection with his appointment. These Options have an exercise price of 45.5 p per share, being the closing mid-market price of Ordinary Shares on 9 November 2015. The Options vest over a three year period as to one third on the first anniversary, one third on the second anniversary and one third on the third anniversary of the Grant Date. All Options granted will vest immediately if the mid-price of Ordinary Shares is maintained at or above £1.00 for ten consecutive trading days. The Options have been granted under the Company's non-EMI share option plan and will expire on the fifth anniversary of the Grant Date.

The Options represent 0.34% of the Company's current issued ordinary share capital. Following the grant of the Options, the total number of options outstanding to subscribe for new Ordinary Shares in the Company is 2,510,000, representing 7.22% of the Company's current issued ordinary share capital.

 

For further information please contact:

Tekcapital Plc		[phone] Ext 305
	Clifford M. Gross	[e-mail]
Allenby Capital Limited (Nominated Adviser & Joint Broker)		[phone]
Jeremy Porter / Alex Brearley
Optiva Securities Limited (Joint Broker)		[phone]
Jeremy King / Vishal Balasingham		[e-mail]
Walbrook PR Ltd		[phone]
Paul Cornelius / Paul McManus		[e-mail]

Tekcapital plc - The World's Largest University Network for Open Innovation

Tekcapital helps clients profit from new, university-developed intellectual properties. With our proprietary discovery search engine, linked to 4,000+ universities in 160 countries, coupled with expert scientific review, we provide a turn-key service to make it easy for clients to find and acquire the IP they need to create a competitive advantage. Tekcapital plc is listed on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com

 

END

 

 

BOAPKCDPDBDBQDK